---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-034834"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2026-05-14T12:48:56+00:00"
generated_at: "2026-05-14T12:50:10.894789+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports Q1 net loss $4.2M, secures up to $40M financing; FDA supports pivotal trial for SENTI-202 in R/R AML

## Summary
- Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.
- Secured up to $40M in senior secured convertible notes from Celadon Partners; initial $10M tranche expected May 2026.
- FDA RMAT meeting supports single-arm multi-center pivotal trial for SENTI-202 in R/R AML after LD chemotherapy.
- Donor X phenotype identified: 50% cCR (7/14) with Donor X NK cells vs 12.5% (1/8) without; longest remission 21+ months.
- Lease modification gain $6.9M; cash burn reduced to $7.5M Q1 2026 from $14.1M Q1 2025.

## SEC filing metadata
- accession: 0001628280-26-034834
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2026-05-14T12:48:56+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/0001628280-26-034834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/snti-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-034834
- JSON: https://secwatch.observer/filing/0001628280-26-034834.json
- Plain text: https://secwatch.observer/filing/0001628280-26-034834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.